Imaging response during therapy with radium-223 (Ra-223) for castration-resistant prostate cancer (CRPC) with bone metastases (BM): A multicenter analysis.

被引：3

作者：

Omlin, Aurelius Gabriel

Daugaard, Gedske

Peer, Avivit

Reichegger, Hermann

Neumann, Avivit

Rosenbaum, Eli

Desax, Marie-Claire

Neiman, Victoria

Petersen, Peter Meidahl

Mueller, Joachim

Cathomas, Richard

Gottfried, Maya

Sarid, David

Gez, Eli

Mermershtain, Wilmosh

Rouvinov, Keren

Mortensen, Jann

Gillessen, Silke

Keizman, Daniel

机构：

[1] Kantonsspital St Gallen, St Gallen, Switzerland

[2] Copenhagen Univ Hosp, Copenhagen, Denmark

[3] Rambam Hlth Care Campus, Haifa, Israel

[4] Cantonal Hosp St Gallen, St Gallen, Switzerland

[5] Rambam Med Ctr, Dept Oncol, Haifa, Israel

[6] Rabin Med Ctr, Dept Oncol, Petah Tiqwa, Israel

[7] Rabin Med Ctr, Davidoff Canc Ctr, Petach-Tikva, Israel

[8] Rigshosp, Dept Oncol, Copenhagen, Denmark

[9] Kantonsspital Chur, Chur, Switzerland

[10] Meir Med Ctr, Lung Canc Unit, Kefar Sava, Israel

[11] Ichilov Hosp, Sourasky Med Ctr, Tel Aviv, Israel

[12] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[13] Soroka Med Ctr, Beer Sheva, Israel

[14] Rigshosp, Nucl Med & PET, Dept Clin Physiol, Copenhagen, Denmark

[15] Tel Aviv Univ, Sackler Sch Med, Div Oncol, Meir Med Ctr,Genitourinary Oncol Serv, Kefar Sava, Israel

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.5057

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5057

引用

页数：3

共 50 条

[21] Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial
Strauss, A.
Parker, C.
Garcia-Vargas, J.
O'Bryan-Tear, G.
Fang, F.
Vogelzang, N. J.
ONKOLOGIE, 2013, 36 : 78 - 78
[22] Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial
Parker, Chris
Garcia-Vargas, Jose E.
O'Bryan-Tear, C. Gillies
Fang, Fang
Vogelzang, Nicholas J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[23] External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (mets) From the ALSYMPCA Trial
Finkelstein, S. E.
Michalski, J. M.
O'Sullivan, J.
Parker, C.
Garcia-Vargas, J.
Sartor, O.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S201 - S201
[24] Hematotoxicity and non-hematological adverse events of Ra-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases.
Ahmadzadehfar, Hojjat
Azgomi, Kambiz
Rogenhofer, Sebastian
Bundschuh, Ralph
Kuerpig, Stefan
Essler, Markus
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
[25] Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).
Alonzi, Roberto
Parker, Chris C.
Tunariu, Nina
Koh, Dow-Mu
Staffurth, John
Blackledge, Matthew D.
Padhani, Anwar R.
Tree, Alison
Stidwill, Helen
Finch, Jessica
Chatfield, Peter
Perry, Sophie
Tovey, Holly
Hall, Emma
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[26] ESTIMATING THE ECONOMIC IMPACT OF RADIUM RA 223 DICHLORIDE (RADIUM-223) IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
Valderrama, A.
Bilir, S. P.
Wehler, E. A.
Seal, B. S.
Wen, L.
Yaldo, A.
Munakata, J.
VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
[27] Time to first skeletal-related event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis
Coleman, R.
Fossa, S.
Chodacki, A.
Wedel, S.
Bruland, O.
Staudacher, K.
Garcia-Vargas, J.
Sartor, O.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S688 - S688
[28] PAIN AND QUALITY OF LIFE (QOL) ANALYSES FROM THE PHASE 3 RANDOMIZED ALSYMPCA STUDY WITH RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS WITH BONE METASTASES
Tomblyn, Michael
Nilsson, Sten
Vogelzang, Nicholas
Sartor, A. Oliver
Cislo, Paul
Van Gool, Renilt
Aksnes, Anne-Kirsti
Parker, Chris
JOURNAL OF UROLOGY, 2013, 189 (04): : E293 - E293
[29] Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why
Gallicchio, Rosj
Mastrangelo, Pietro A.
Nardelli, Anna
Mainenti, Pier Paolo
Colasurdo, Antonio P.
Landriscina, Matteo
Guglielmi, Giuseppe
Storto, Giovanni
TUMORI JOURNAL, 2019, 105 (05): : 367 - 377
[30] Radium-223 dichloride (Ra-223) hematologic and 1.5-year posttreatment safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from ALSYMPCA
Conti, Peter
Michalski, Jeff
Skjorestad, Irene
Wahba, Mona
Nilsson, Sten
JOURNAL OF NUCLEAR MEDICINE, 2014, 55

← 1 2 3 4 5 →